Question explored with the scientific record
Quetiapine as a never ending drug to take every day
The short version: quetiapine is a drug with modest evidence for maintenance in some conditions and well-documented metabolic harms that accumulate over time. The burden of proof for indefinite daily use has not been met.
The evidence for quetiapine as a maintenance drug is weak compared to other options. In major depressive disorder, the 2015 WFSBP guidelines give quetiapine only a CE_B rating (limited positive evidence from controlled trials) for maintenance, placing it below SSRIs and SNRIs [1]. In bipolar disorder, a 4-year naturalistic study found quetiapine monotherapy roughly equal to lithium for preventing depressive relapse, but the dropout rate was 56% in the quetiapine group [2]. In schizophrenia, a 2016 network meta-analysis of 56 trials ranked quetiapine below olanzapine and most long-acting injectables for relapse prevention [7]. The CONSTATRE trial found quetiapine had a 31.3% relapse rate over two years compared to 16.5% for risperidone LAI [4].
The metabolic risks are real and dose-dependent. A 2015 meta-analysis of 257 trials found quetiapine causes about 1.1 kg of weight gain on average [25]. But the CATIE trial showed 7% of patients on quetiapine gained more than 7% of their baseline weight [23]. A Jordanian retrospective study found metabolic syndrome prevalence rose from 14.3% to 37.4% after six months on second-generation antipsychotics including quetiapine [14]. In adolescents, quetiapine caused significant cholesterol increases and thyroid hormone decreases over six months [17]. Low-dose quetiapine (25-100 mg) used for insomnia still causes weight gain of 2-5 kg over 6-12 months [20, 21]. One case report documented fatal hepatotoxicity at just 12.5 mg twice daily [20].
The evidence is thin on long-term outcomes beyond two years. Most trials run 6-12 months. The longest study here is 4 years [2], and it had a 56% dropout rate. No study compared indefinite quetiapine use to no treatment over decades. The manufacturer (AstraZeneca) funded many of the key trials. The 2015 WFSBP guidelines note that maintenance duration beyond 6-9 months is "not fully determined" [1].
My call: quetiapine has a role for short-to-medium term stabilization in bipolar disorder and schizophrenia when other options fail, but the evidence does not support indefinite daily use as a default. The metabolic harms are cumulative and the long-term safety data is missing. Confidence: moderate.
Sources used 10
-
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015
A comprehensive, evidence-based update (2015) of the World Federation of Societies of Biological Psychiatry guidelines for maintenance treatment of unipolar major depressive disorder, detailing pharmacological and non-pharmacological strategies (including antidepressants, lithiu…
DOI: 10.3109/15622975.2014.1001786 -
Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: A 4-year follow-up naturalistic study
This 4-year naturalistic follow-up study compared quetiapine and classical mood stabilizers (alone or in combination) in 232 bipolar disorder patients, finding that quetiapine plus lithium or quetiapine plus valproate produced the strongest maintenance of euthymia, while quetiap…
DOI: 10.1016/j.jad.2008.01.017 -
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-acting Injectable Versus Quetiapine: Randomized, Long-term, Open-label, Clinical Trial Results (constatre)
The CONSTATRE study compares long-acting injectable risperidone versus quetiapine over two years in stable patients with schizophrenia or related disorders, finding a significantly longer relapse-free period and better PANSS outcomes with risperidone LAI, with similar adverse ev…
DOI: 10.1016/s0924-9338(09)71253-2 -
Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
A comprehensive network meta-analysis of 56 randomized controlled trials (n = 10,177) comparing 18 antipsychotics and placebo for long-term relapse prevention in schizophrenia, finding olanzapine and several long-acting injectable agents to provide favorable relapse reduction wi…
DOI: 10.1192/bjpo.bp.115.002576 -
The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
A retrospective study of 91 Jordanian adults on long-term second-generation antipsychotics shows a significant rise in metabolic syndrome and its components after six months, with BMI, triglycerides, fasting glucose, and blood pressure increasing and metabolic syndrome prevalenc…
DOI: 10.3390/medicina55070320 -
P.3.03 The antidepressant effect of subconvulsive stimulation of the prefrontal cortex as compared to electroconvulsive therapy
This study evaluates the metabolic side effects of second generation antipsychotics (SGAs) in antipsychotic-naive adolescents, revealing significant weight and BMI increases associated with olanzapine and risperidone, but not quetiapine, over a 6-month treatment period.
DOI: 10.1016/S0924-977X(07)70084-6 -
Safety of Low Doses of Quetiapine When Used for Insomnia
A literature review assessing the safety of low-dose quetiapine for insomnia finds limited evidence of sleep benefit but notable safety concerns (weight gain, hepatotoxicity, akathisia, RLS) across small prospective/open-label trials, retrospective cohorts, and case reports, lea…
DOI: 10.1345/aph.1q697 -
Metabolic Consequences of Using Low-Dose Quetiapine for Insomnia in Psychiatric Patients
This study documents the metabolic consequences, specifically weight gain and increased body mass index, associated with low-dose quetiapine prescribed for insomnia in psychiatric patients, highlighting significant changes despite the low dosage.
DOI: 10.1007/s10597-009-9200-0 -
Metabolic Findings From the CATIE Trial and Their Relation to Tolerability
Metabolic findings from the CATIE trial indicate high metabolic syndrome prevalence in schizophrenia, with olanzapine and other antipsychotics driving weight gain and dyslipidemia, impacting tolerability and necessitating routine metabolic monitoring.
DOI: 10.1017/s1092852900026663 -
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
This umbrella systematic review and meta-analysis synthesizes weight-change effects across 54 drugs from 257 randomized trials (84,696 participants), identifying which drugs are associated with weight gain or loss and highlighting methodological limitations to guide clinical cho…
DOI: 10.1210/jc.2014-3421